Ulcerative Colitis and Crohn's Disease Observational Studies
Predictive value of fecal calprotectin measurement in severe ulcerative colitis
Principal Investigator: Peter Higgins, MD, PhD, MSc
This two-center prospective study will study if the measurements of fecal calprotectin (FCP) performed serially during admission in patients with severe ulcerative colitis may be predictive of need to escalate medical therapy. Additionally, this study will investigate if using FCP can predict outcomes of interest, including readmission, surgery, and Clostridium difficile infection at 30 and 100 days.
BÜHLMANN calprotectin ELISA method comparison to predictive device for FDA clearance
Principal Investigator: Peter Higgins, MD, PhD, MSc
An instrument was developed by BÜHLMANN to test calprotectin levels in stool specimens in Europe, however, it is not approved by the FDA for use in the United States. This instrument would aid in the diagnosis of inflammatory bowel diseases (IBD), as well as aid in the differentiation of active versus inactive inflammation of IBD, irritable bowel syndrome (IBS), and other functional bowel syndromes.
Inflammatory Bowel Disease (IBD) Databank
Principal Investigator: Ellen Zimmermann, MD
In this study we collect information on patients with IBD and their family. We are interested in the demographics, genetics, and extent of disease at this time. Participants in this study give a blood sample for genetic analysis and take surveys bi-annually. In the future, we plan to collect tissue or stool samples as part of this study to learn more about how the immune system works in people with IBD. The duration of this study is open-ended. Adults with IBD and their family are welcome to participate.
Contact person for Dr. Higgins' studies:
Contact person for Dr. Zimmermann's study:
